PHA-739358 for the Treatment of Multiple Myeloma

Nerviano Medical Sciences

Status and phase: Terminated; Phase 2

Conditions: Multiple Myeloma

Treatments: Drug: PHA-739358

Study type: Interventional

Funder types: Industry

Identifiers

NCT00872300

AURA-6202-011

Details and patient eligibility

About

The purpose of this study is to determine the antitumor activity of PHA-739358 as single agent IV infusion in adult patients with Multiple Myeloma who have a history of at least 2 previous lines of treatment for the disease.

Enrollment: 7 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• active multiple myeloma progressing after at least 2 prior lines of treatment
• measurable disease
• t(4;14) translocation
• life expectancy of at least 3 months

Exclusion criteria

• uncontrolled hypertension
• myocardial infarction, unstable angina, symptomatic congestive heart failure, cerebrovascular accident in the past 6 months.
• pregnancy or breast feeding
• active infections, including HIV

Trial design

Primary purpose: Supportive Care

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

7 participants in 1 patient group

1

Experimental group

Treatment:

Drug: PHA-739358